As with imatinib and crizotinib, patients presenting with activating EGFR mutations display significant responses to the EGFR inhibitors erlotinib or gefitinib (also known as Iressa) [29], and these have been approved for the treatment of EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.